Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned an average rating of “Moderate Buy” from the eighteen brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, ten have given a buy recommendation and four have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $34.0667.

Several brokerages recently issued reports on DYN. Royal Bank Of Canada reduced their target price on shares of Dyne Therapeutics from $25.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, July 29th. Stifel Nicolaus cut their target price on shares of Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, July 31st. Chardan Capital dropped their price objective on shares of Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, July 29th. Evercore ISI reiterated an “outperform” rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Dyne Therapeutics from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, July 15th.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $17.12 on Friday. The company’s 50 day simple moving average is $13.80 and its 200 day simple moving average is $11.76. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of -4.44 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $35.68.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox sold 2,640 shares of the stock in a transaction on Friday, September 5th. The shares were sold at an average price of $13.41, for a total value of $35,402.40. Following the transaction, the chief executive officer directly owned 199,539 shares of the company’s stock, valued at $2,675,817.99. This trade represents a 1.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 14.14% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of large investors have recently bought and sold shares of the business. Darwin Wealth Management LLC lifted its stake in shares of Dyne Therapeutics by 0.5% in the 3rd quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock worth $2,195,000 after acquiring an additional 861 shares during the period. Ameritas Investment Partners Inc. increased its holdings in Dyne Therapeutics by 11.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after acquiring an additional 955 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Dyne Therapeutics by 5.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company’s stock valued at $237,000 after acquiring an additional 1,115 shares in the last quarter. Arizona State Retirement System increased its holdings in Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company’s stock valued at $183,000 after acquiring an additional 1,481 shares in the last quarter. Finally, Caxton Associates LLP grew its holdings in shares of Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after buying an additional 1,627 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.